GlassScriptPhysician profile
Pamela Landon
NPI 1477500700
$1,101.54
in general payments reported to CMS, 2019-2025
22 companies · $99.45 in 2025
The $99.45 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.16 · 2020: $110 · 2021: $478 · 2022: $93.43 · 2023: $110 · 2024: $151 · 2025: $99.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $151.76 | 2020-2023 | Lumakras |
| Glaxosmithkline, LLC. | $123.43 | 2021 | |
| Haemonetics Corporation | $108.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $103.56 | 2021-2024 | |
| Abbvie INC. | $102.86 | 2023-2025 | |
| Medtronic, INC. | $68.68 | 2021 | |
| Janssen Scientific Affairs, LLC | $59.16 | 2019 | |
| Merck Sharp & Dohme LLC | $43.67 | 2023-2024 | Keytruda, Lenvima |
| Daiichi Sankyo INC. | $42.41 | 2020-2024 | Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $41.29 | 2021 | |
| Astellas Pharma US INC | $31.53 | 2025 | Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2024 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $25.79 | 2021 | |
| Pfizer INC. | $24.19 | 2024 | |
| Karyopharm Therapeutics INC. | $23.80 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.47 | 2021 | |
| Janssen Biotech, INC. | $19.20 | 2024 | Talvey, Tecvayli, Imbruvica |
| Sobi, INC | $18.48 | 2023 | |
| Lilly USA, LLC | $17.25 | 2022 | |
| Taiho Oncology, INC. | $16.78 | 2021 | |
| Blueprint Medicines Corporation | $15.13 | 2022 | |
| Clovis Oncology, INC. | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Landon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.